Gilead Sciences, Inc. (GILD) Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Gilead Sciences, Inc. (GILD) is a biopharmaceutical company based in Foster City, California, focusing on innovative medicines that address critical global health needs. Established in 1987 and classified under drug manufacturers in the biotechnology sector, Gilead develops a robust portfolio of treatments, particularly for HIV/AIDS, COVID-19, viral hepatitis, and oncology. Notable products include Biktarvy and Veklury. Analysts have a strong “buy” recommendation on Gild, with a target price reaching up to $119.00 per share, supported by a significant annual revenue of approximately $27.8 billion. This growth outlook reflects an increasing demand for pharmaceuticals driven by an aging population and evolving healthcare requirements.
Stock Performance and Investor Sentiment
Currently, Gilead Sciences’ stock is trading at $83.94, which is above the target mean price of $82.33. Compared to the target high of $119.00, there’s a potential upside of roughly 42%, making it an attractive investment opportunity. With 1,244,989,952 shares outstanding and only 19,797,475 shares sold short, the short percent of float is at 0.0159%. This suggests strong confidence from investors regarding the company’s performance. The asset’s current price is also above its fifty-day moving average of $76.77, indicating solid short-term momentum. Over the past year, Gilead has experienced a 52-week range of $62.07 to $87.87, reflecting a healthy performance trend.
Financial Health and Analyst Insights
Gilead reports a total revenue of approximately $27.8 billion; however, the absence of EBITDA data limits a full assessment of profitability and operational efficiency. Nevertheless, the strong revenue signals a solid business foundation poised for growth. Analysts project a bullish outlook with a target low price of $68.50 and a median price of $79.50, indicating widespread optimism among the 26 analysts tracking the stock. This positive sentiment reinforces Gilead’s attractiveness as a potential investment in the biotech space, especially in light of increasing global healthcare demands.
| Metric | Value |
|---|---|
| Market Cap | $104.5b |
| Total Debt | $23.3b |
| Total Cash | $3.8b |
| Shares Outstanding | 1.2b |
| Float Shares | 1.2b |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.